Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report

Metastatic primary cutaneous extramammary Paget disease (EMPD) is a rare clinical entity with a 5-year survival <10% and no standard therapy. We report the first case to our knowledge of metastatic EMPD with treatment response to checkpoint inhibitor immunotherapy. The patient had diffusely...

Full description

Bibliographic Details
Main Authors: Brendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, Mario E. Lacouture, Soleen Ghafoor, Anthony M. Rossi, David N. Assis, Ying-Bei Chen, Klaus J. Busam, Yelena Y. Janjigian, Komal Jhaveri, Darren R. Feldman, Anne Capozzi, Vanessa Figueroa, Dean F. Bajorin, Jonathan E. Rosenberg, Travis J. Hollmann, Samuel A. Funt
Format: Article
Language:English
Published: Karger Publishers 2021-03-01
Series:Case Reports in Oncology
Subjects:
extramammary paget disease
immunotherapy
nivolumab
ipilimumab
immune checkpoint blockade
Online Access:http://prod.karger.com/Article/FullText/514345

Internet

http://prod.karger.com/Article/FullText/514345

Similar Items